MA45187A - Combinaisons pharmaceutiques - Google Patents

Combinaisons pharmaceutiques

Info

Publication number
MA45187A
MA45187A MA045187A MA45187A MA45187A MA 45187 A MA45187 A MA 45187A MA 045187 A MA045187 A MA 045187A MA 45187 A MA45187 A MA 45187A MA 45187 A MA45187 A MA 45187A
Authority
MA
Morocco
Prior art keywords
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Application number
MA045187A
Other languages
English (en)
French (fr)
Inventor
Zhu Alexander Cao
Giordano Caponigro
Original Assignee
Zhu Alexander Cao
Giordano Caponigro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA45187(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zhu Alexander Cao, Giordano Caponigro filed Critical Zhu Alexander Cao
Publication of MA45187A publication Critical patent/MA45187A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA045187A 2016-06-03 2017-06-02 Combinaisons pharmaceutiques MA45187A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
MA45187A true MA45187A (fr) 2019-04-10

Family

ID=60477982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045187A MA45187A (fr) 2016-06-03 2017-06-02 Combinaisons pharmaceutiques

Country Status (26)

Country Link
US (3) US10485788B2 (enExample)
EP (1) EP3463345B1 (enExample)
JP (2) JP6805336B2 (enExample)
KR (1) KR102439911B1 (enExample)
CN (1) CN109890386B (enExample)
AU (1) AU2017275650B2 (enExample)
BR (1) BR112018074941A2 (enExample)
CA (1) CA3026361A1 (enExample)
CL (1) CL2018003421A1 (enExample)
CO (1) CO2019000010A2 (enExample)
CR (1) CR20190002A (enExample)
DK (1) DK3463345T3 (enExample)
FI (1) FI3463345T3 (enExample)
HU (1) HUE060653T2 (enExample)
IL (1) IL263431A (enExample)
MA (1) MA45187A (enExample)
MX (1) MX387795B (enExample)
PH (1) PH12018502549A1 (enExample)
PL (1) PL3463345T3 (enExample)
PT (1) PT3463345T (enExample)
RU (1) RU2759669C2 (enExample)
SG (1) SG11201810793XA (enExample)
SI (1) SI3463345T1 (enExample)
UA (1) UA125436C2 (enExample)
WO (1) WO2017210538A1 (enExample)
ZA (1) ZA201900019B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2021069504A1 (en) * 2019-10-11 2021-04-15 F. Hoffmann-La Roche Ag Drug dosage determination devices and methods
EP4103286A4 (en) * 2020-02-10 2024-03-20 Cedars-Sinai Medical Center METHOD OF TREATMENT OF PANCREATIC CANCER
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
WO2024126660A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
PL2324008T3 (pl) 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylopirazole jako inhibitory kinazy białkowej
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CA2838736A1 (en) * 2011-06-07 2012-12-13 Caris Mpi, Inc. Molecular profiling for cancer
US11007194B2 (en) * 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
WO2013078264A1 (en) 2011-11-23 2013-05-30 Novartis Ag Pharmaceutical formulations
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
JP6342396B2 (ja) * 2012-08-07 2018-06-13 ノバルティス アーゲー Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
PL3702351T3 (pl) * 2012-10-19 2024-04-02 Array Biopharma, Inc. Formulacja zawierająca inhibitor mek
BR112015009134A2 (pt) * 2012-10-25 2017-07-04 Glaxosmithkline Llc combinação
DK2976106T3 (da) 2013-03-21 2021-06-14 Array Biopharma Inc Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer
JP6285933B2 (ja) * 2013-07-18 2018-02-28 株式会社ダイセル 酸化物の製造方法
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
MX2016007653A (es) * 2013-12-12 2016-10-13 Novartis Ag Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer.
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
WO2016155670A1 (zh) * 2015-04-01 2016-10-06 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
US20170027951A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas

Also Published As

Publication number Publication date
US11376239B2 (en) 2022-07-05
EP3463345B1 (en) 2022-11-02
ZA201900019B (en) 2023-04-26
CA3026361A1 (en) 2017-12-07
US20200230108A1 (en) 2020-07-23
BR112018074941A2 (pt) 2019-03-12
EP3463345A4 (en) 2020-02-26
RU2759669C2 (ru) 2021-11-16
MX387795B (es) 2025-03-19
PT3463345T (pt) 2023-01-06
EP3463345A1 (en) 2019-04-10
AU2017275650B2 (en) 2023-06-01
CO2019000010A2 (es) 2019-05-21
CN109890386B (zh) 2022-05-24
UA125436C2 (uk) 2022-03-09
RU2018146812A (ru) 2020-07-09
KR20190119507A (ko) 2019-10-22
PL3463345T3 (pl) 2023-02-06
US20190105303A1 (en) 2019-04-11
PH12018502549A1 (en) 2019-04-08
CN109890386A (zh) 2019-06-14
CR20190002A (es) 2019-06-10
WO2017210538A1 (en) 2017-12-07
IL263431A (en) 2019-01-31
AU2017275650A1 (en) 2019-01-17
DK3463345T3 (da) 2023-01-09
RU2018146812A3 (enExample) 2020-10-09
JP2019525948A (ja) 2019-09-12
SG11201810793XA (en) 2018-12-28
MX2018014973A (es) 2019-12-18
KR102439911B1 (ko) 2022-09-05
JP6805336B2 (ja) 2020-12-23
JP2021054832A (ja) 2021-04-08
US10485788B2 (en) 2019-11-26
CL2018003421A1 (es) 2019-07-19
FI3463345T3 (fi) 2023-01-31
HUE060653T2 (hu) 2023-04-28
US20230044943A1 (en) 2023-02-09
SI3463345T1 (sl) 2023-02-28

Similar Documents

Publication Publication Date Title
IL258931A (en) Therapeutic compounds and methods
MA50541A (fr) Formulations pharmaceutiques
SI3529248T1 (sl) Farmacevtske spojine
EP3513809A4 (en) MEDICAL COMPOSITION
EP3541385A4 (en) PHARMACEUTICAL FORMULATIONS
MA42303A (fr) Formulations pharmaceutiques
BR112017027227A2 (pt) Agente anti-câncer
EP3463345A4 (en) PHARMACEUTICAL COMBINATIONS
DK3199161T3 (da) Farmaceutisk præparat
DK3529240T3 (da) Farmaceutiske forbindelser
EP3424940A4 (en) Radiolabeled drug
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
EP3437644A4 (en) MEDICINE
MA44987A (fr) Formulations de médicaments améliorées
EP3527216A4 (en) MEDICINE
MA49837A (fr) Compositions pharmaceutiques
EP3399976C0 (en) BENZOTHIAZOLE AMPHOPHILES
DK3280447T3 (da) Farmaceutiske formuleringer
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
EP3334447A4 (en) CCK2R-drug conjugates
DK3728220T3 (da) Farmaceutiske forbindelser
HUE069648T2 (hu) Gyógyszerészeti készítmény
DK3432887T3 (da) Anti-tuberkulosemiddel
EP3646865A4 (en) MEDICINE
DK3601277T3 (da) Farmaceutisk formulering